The global fill-finish manufacturing market for primary packaging of pre-filled syringes is estimated to be valued at US$ 16.41 billion in 2024 and is expected to exhibit a CAGR of 9.2% over the forecast period from 2024 to 2031. Primary packaging for pre-filled syringes comprises of the syringe body along with accessories such as the needle, needle shield, and plungers. There has been a significant rise in demand for pre-filled syringes for parenteral drug administration over the conventional vial and ampoule format, owing to advantages such as prevention of contamination during drug reconstitution, repetitive dosing accuracy, and ease of administration. Moreover, the syringe format allows for integration of safety mechanisms to prevent needle stick injuries. Fill-finish manufacturing involves the assembly, filling and packaging of the parenteral drugs or vaccines into their primary containers under aseptic conditions.

Global Fill-Finish Manufacturing Market is estimated to be valued at US$ 16.41 billion in 2024 and is expected to exhibit a CAGR of 9.2% over the forecast period from 2024 to 2031.

Key Takeaways

Key players operating in the Fill-Finish Manufacturing Market Demand for primary packaging of pre-filled syringes include Asymchem Inc., Syntegon Technology GmbH, I.M.A. INDUSTRIA MACCHINE AUTOMATICHE S.P.A, West Pharmaceutical Services, Inc., Gerresheimer AG, AptarGroup, Inc., Dätwyler Holding Inc., Stevanato Group, OPTIMA, SGD Pharma, Nipro Corporation, Bausch Advanced Technology Group, and Berry Global Inc. These players are focusing on capacity expansions and technology advancements to cater to the growing demand for pre-filled syringes.

The global market provides significant opportunities in terms of innovation in packaging configurations and enhanced safety solutions. Continued development of novel biologics and large molecule drugs also presents lucrative growth prospects for fill-finish manufacturing of pre-filled syringes.

Key players are also witnessing high demand for their fill-finish services from multinational pharmaceutical manufacturers looking to expand in international markets. This is encouraging global expansion efforts of fill-finish service providers in high growth regions such as Asia Pacific, Middle East, and Latin America through acquisitions and establishment of new production facilities.

Market Drivers

One of the key drivers for the fill-finish manufacturing market for pre-filled syringes is the increasing incidence of chronic and lifestyle diseases globally. This has augmented the demand for parenteral drug delivery significantly. Pre-filled syringes offer accuracy, safety and patient compliance benefits over conventional drug packaging which is positively impacting their uptake.

Market Restraints

However, the market faces certain restraints such as the premium pricing of pre-filled syringes compared to vials. Moreover, lack of sophistication in certain developing markets restricts the adoption of advanced drug delivery systems like pre-filled syringes. Stringent regulatory requirements for fill-finish manufacturing operations also add to the complexity and costs.

Segment Analysis

The fill finish manufacturing market can be segmented by product into consumables and equipment. The consumables segment dominated the market in 2020 as consumables such as vials, syringes, bags, cartridges, stoppers, seals are required in high volumes for various fill finish processes. Consumables accounted for over 60% of the total market share in 2020.

The equipment segment can be further divided into liquid handling equipment, capping-sealing equipment, labeling-coding equipment, inspection and leak testing equipment. The liquid handling equipment sub segment held the largest share in 2020 as it finds wide application in filling of liquid drugs in various containers. Liquid handling equipment facilitates smooth and precise filling and helps minimize contamination risks, thereby maintaining sterility.

Global Analysis

North America accounted for the largest share of over 35% of the global fill finish manufacturing market in 2020 owing to escalating biopharmaceutical R&D activities and strong presence of major players in the US and Canada. Europe was the second largest regional market led by robust pharmaceutical manufacturing industry in Germany, UK, France and Italy along with significant government support for pharmaceutical research.

The Asia Pacific region is anticipated to witness the fastest growth over the forecast period with a CAGR of around 11%. This can be attributed to expanding biologics production in China, India, and South Korea coupled with rising healthcare expenditure of populations in Asia Pacific countries. Additionally, tax incentives and availability of low-cost skilled labor force are encouraging biopharma companies to set up manufacturing facilities in Asian nations.